Chronic kidney disease in type 2 diabetes mellitus research hub

(21839) A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.

This study is looking at how two medicines, finerenone (Kerendia) and empagliflozin (Jardiance), affect people with chronic kidney disease and type 2 diabetes. We want to see if using both together is better than using just one in improving kidney health.